Richard Joseph

Employment

• Daiichi Sankyo Inc

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (65)

• Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
  Clinical Cancer Research 2018 DOI: 10.1158/1078-0432.CCR-17-2386
  +Save
• Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
  Clinical Cancer Research 2018 DOI: 10.1158/1078-0432.CCR-18-0309
  +Save
• Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients
  Surgical Oncology 2018 DOI: 10.1016/j.suronc.2017.10.005
  +Save
• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
  The Lancet 2017 DOI: 10.1016/S0140-6736(16)32455-2
  +Save
• BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor
  BMC Urology 2017 DOI: 10.1186/s12894-017-0209-3
  +Save
• Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
  European Journal of Cancer 2017 DOI: 10.1016/j.ejca.2017.01.009
  +Save
• Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
  Urologic Oncology: Seminars and Original Investigations 2017 DOI: 10.1016/j.urolonc.2017.01.017
  +Save
• High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma
  Oncogene 2016 DOI: 10.1038/onc.2015.221
  +Save
• Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod
  Melanoma Research 2016 DOI: 10.1097/CMR.0000000000000247
  +Save
• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
  Journal for ImmunoTherapy of Cancer 2016 DOI: 10.1186/s40425-016-0180-7
  +Save